Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells

Oncology Reports

Volumn 28, Issue 4, 2012, Pages 1146-1152

  Masuda, Kenta ^a   Banno, Kouji ^a   Yanokura, Megumi ^a   Tsuji, Kosuke ^a   Kobayashi, Yusuke ^a   Kisu, Iori ^a   Ueki, Arisa ^a   Yamagami, Wataru ^a   Nomura, Hiroyuki ^a   Tominaga, Eiichiro ^a   Susumu, Nobuyuki ^a   Aoki, Daisuke ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Cervical cancer; Chemosensitivity; CPT 11; DNA hypermethylation; WRN

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CISPLATIN; DOXORUBICIN; IRINOTECAN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; COLLAGEN GEL DROPLET EMBEDDED CULTURE DRUG SENSITIVITY TEST; CONTROLLED STUDY; DNA EXTRACTION; DNA METHYLATION; DRUG SENSITIVITY; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA EXTRACTION; UTERINE CERVIX CANCER; WERNER GENE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; AZACITIDINE; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; EXODEOXYRIBONUCLEASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECQ HELICASES; RNA, SMALL INTERFERING; TOPOISOMERASE I INHIBITORS; UTERINE CERVICAL NEOPLASMS;

EID: 84866461237     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1912     Document Type: Article

References (48)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer Statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Forouzanfar MH, Foreman KJ, Delossantos AM, et al: Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 378: 1461-1484, 2011.
3. zur Hausen H: Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res 49: 4677-4681, 1989.
4. Muñoz N, Bosch FX, de Sanjosé S, et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003. (Pubitemid 36159887)
5. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
6. Jones PA and Laird PW: Cancer epigenetics comes of age. Nat Genet 21: 163-167, 1999. (Pubitemid 29070360)
7. Baylin SB and Herman JG: DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16: 168-174, 2000. (Pubitemid 30169152)
8. Esteller M: Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16: 50-59, 2007.
9. Virmani AK, Muller C, Rathi A, Zoechbauer-Mueller S, Mathis M and Gazdar AF: Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 7: 584-589, 2001. (Pubitemid 32707982)
10. INK4A in primary gynecologic malignancy. Cancer Lett 136: 231-235, 1999.
11. Dong SM, Kim H-S, Rha S-H and Sidransky D: Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res 7: 1982-1986, 2001. (Pubitemid 32994835)
12. Kuzmin I, Liu L, Dammann R, et al: Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection. Cancer Res 63: 1888-1893, 2003. (Pubitemid 36460854)
13. Agrelo R, Cheng W-H, Setien F, et al: Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci USA 103: 8822-8827, 2006. (Pubitemid 43878103)
14. Yu CE, Oshima J, Wijsman EM, et al: Mutations in the consensus helicase domains of the Werner syndrome gene. Werner's Syndrome Collaborative Group. Am J Hum Genet 60: 330-341, 1997. (Pubitemid 27058404)
15. Muftuoglu M, Oshima J, Kobbe C, Cheng W-H, Leistritz DF and Bohr VA: The clinical characteristics of Werner syndrome: molecular and biochemical diagnosis. Hum Genet 124: 369-377, 2008.
16. Goto M, Miller RW, Ishikawa Y and Sugano H: Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev 5: 239-246, 1996.
17. Epstein CJ, Martin GM, Schultz AL and Motulsky AG: Werner's syndrome a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. Medicine 45: 177-221, 1966.
18. Huang S, Lee L, Hanson NB, et al: The spectrum of WRN mutations in Werner syndrome patients. Hum Mutat 27: 558-567, 2006. (Pubitemid 43865729)
19. Shaheen AC, Malcolm CC, Neil RJC, et al: Two novel regions of interstitial deletion on chromosome 8p in colorectal cancer. Oncogene 18: 657-665,1999.
20. Armes JE, Hammet F, de Silva M, et al: Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogene 23: 5697-5702, 2004. (Pubitemid 39093049)
21. Futami K, Takagi M, Shimamoto A, Sugimoto M and Furuichi Y: Increased chemotherapeutic activity of camptothecin in cancer cells by siRNA-induced silencing of WRN helicase. Biol Pharm Bull 30: 1958-1961, 2007. (Pubitemid 47607770)
22. Hsiang YH, Hertzberg R, Hecht S and Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878, 1985. (Pubitemid 16211028)
23. Hsiang YH, Lihou MG and Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082, 1989. (Pubitemid 19239347)
24. Thigpen T: The role of chemotherapy in the management of carcinoma of the cervix. Cancer J 9: 425-432, 2003.
25. Takeuchi S, Dobashi K, Fujimoto S, et al: A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers. Gan To Kagaku Ryoho 18: 1681-1689, 1991 (In Japanese).
26. Susumu N, Aoki D, Noda T, et al: Diagnostic clinical application of two-color fluorescence in situ hybridization that detects chromosome 1 and 17 alterations to direct touch smear and liquid-based thin-layer cytologic preparations of endometrial cancers. Int J Gynecol Cancer 15: 70-80, 2005. (Pubitemid 40194336)
27. Kawaguchi M, Banno K, Susumu N, et al: Successful analysis of anticancer drug sensitivity by CD-DST using pleural fluid and ascites from patients with advanced ovarian cancer: case reports. Anticancer Res 25: 3547-3551, 2005. (Pubitemid 41105239)
28. Kawamura M, Gika M, Abiko T, et al: Clinical evaluation of chemosensitivity testing for patients with unresectable non-small cell lung cancer (NSCLC) using collagen gel droplet embedded culture drug sensitivity test (CD-DST). Cancer Chemother Pharmacol 59: 507-513, 2007. (Pubitemid 46122329)
29. Leppard JB and Champoux JJ: Human DNA topoisomerase I: relaxation, roles, and damage control. Chromosoma 114: 75-85, 2005. (Pubitemid 41030970)
30. Covey JM, Jaxel C, Kohn KW and Pommier Y: Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 49: 5016-5022, 1989. (Pubitemid 19239335)
31. Shao RG, Cao CX, Zhang H, Kohn KW, Wold MS and Pommier Y: Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes. EMBO J 18: 1397-1406, 1999. (Pubitemid 29110323)
32. Wan S, Capasso H and Walworth NC: The topoisomerase I poison camptothecin generates a Chk1-dependent DNA damage checkpoint signal in fission yeast. Yeast 15: 821-828, 1999.
33. Cliby WA, Lewis KA, Lilly KK and Kaufmann SH: S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem 277: 1599-1606, 2002. (Pubitemid 34968919)
34. Seiler JA, Conti C, Syed A, Aladjem MI and Pommier Y: The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol Cell Biol 27: 5806-5818, 2007. (Pubitemid 47257835)
35. Koster DA, Palle K, Bot ESM, Bjornsti M-A and Dekker NH: Antitumour drugs impede DNA uncoiling by topoisomerase I. Nature 448: 213-217, 2007. (Pubitemid 47067371)
36. Patro BS, Frøhlich R, Bohr VA and Stevnsner T: WRN helicase regulates the ATR-CHK1-induced S-phase checkpoint pathway in response to topoisomerase-I-DNA covalent complexes. J Cell Sci 124: 3967-3979, 2011.
37. Christmann M, Tomicic MT, Gestrich C, Roos WP, Bohr VA and Kaina B: WRN protects against topo I but not topo II inhibitors by preventing DNA break formation. DNA Repair 7: 1999-2009, 2008.
38. Abraham RT: Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15: 2177-2196, 2001.
39. Shiloh Y: ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3: 155-168, 2003.
40. Versini G, Comet I, Wu M, Hoopes L, Schwob E and Pasero P: The yeast Sgs1 helicase is differentially required for genomic and ribosomal DNA replication. EMBO J 22: 1939-1949, 2003. (Pubitemid 36460150)
41. Sugiyama T, Yakushiji M, Noda K, et al: Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 58: 31-37, 2000. (Pubitemid 30045307)
42. McGuire WP, Blessing JA, Moore D, Lentz SS and Photopulos G: Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 14: 792-795, 1996. (Pubitemid 26085522)
43. Rose PG, Blessing JA, Gershenson DM and McGehee R: Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 17: 2676-2680, 1999. (Pubitemid 29415223)
44. Banno K, Yanokura M, Kawaguchi M, et al: Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes. Int J Oncol 31: 713-720, 2007.
45. Cervical cancer guideline (Version 1. 2012). NCCN Clinical Practice Guidelines in Oncology.
46. Treatment Guidelines for cervical cancer. Japan Society of Gynecologic Oncology. Kanehara & Co., 2011.
47. Benedetti-Panici P, Greggi S, Colombo A, et al: Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 20: 179-188, 2002. (Pubitemid 34032610)
48. Chang TC, Lai CH, Hong JH, et al: Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. J Clin Oncol 18: 1740-1747, 2000. (Pubitemid 30220553)